Oncology
Global oncology R&D and innovations continue to expand, bringing forward new therapies for advanced cancers and some of the most state-of-the-art technologies in pharmaceutical development. These therapies represent the largest area of collective research and the largest overall area by drug prescription.
​
Oncology drug development has moved from a drug-centered to a patient-centered approach.
Next-generation therapies like gene-therapy, CART or NK cell therapy, promise better outcomes for cancer patients. However, despite significant advances in treatment, the global oncology community and patients continue to struggle with disparities in access and care. With the new but also more expensive innovations come more demanding requirements from payers and regulators.
To successfully tackle these requirements, capabilities in oncology management should focus on:​
​
We support our clients in every aspect of pharmaceutical excellence, including product strategy, process transformation and capability enhancement.
​
This means harnessing available data sources, utilization of digital platforms, navigation through a changing Payer & Reimbursement landscape and collaboration with academic centers and patient organizations, in order to demonstrate value to decision-making audiences.
​
In addition, by focusing on emerging new technologies and analytics, which are driving change throughout the pharma industry value chain, we will support you strengthen your competitive position to better meet the changing needs of your audiences.